Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 5/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 2/20 | 0.43 |
| ▸ | AGXT | P21549 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.43 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.42 |
| ▸ | CLK1 | P49759 | 1/20 | 0.42 |
| ▸ | CLK2 | P49760 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | PDE2A | O00408 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24737347 | 0.84 | APP (0.49) | APPNPC1RAB9AMAOBIDO1 | |
| SCHEMBL1275205 | 0.80 | PIN1 (0.49) | MAOBALDH1A1LMNACLK4POLB | |
| SCHEMBL1415469 | 0.80 | ALDH1A1 (0.57) | RAB9ASMN1; SMN2ALDH1A1LMNACLK4 | |
| SCHEMBL31080534 | 0.80 | NPC1 (0.61) | APPNPC1RAB9AMAOBIDO1 | |
| SCHEMBL14958421 | 0.79 | APP (0.58) | APPNPC1RAB9AMAOBIDO1 | |
| SCHEMBL31254878 | 0.79 | PDE2A (0.46) | APPNPC1RAB9AMAOBIDO1 | |
| SCHEMBL24738071 | 0.79 | APP (0.50) | APPNPC1RAB9AMAOBIDO1 | |
| SCHEMBL6401853 | 0.79 | APP (0.50) | APPNPC1RAB9AMAOBIDO1 | |
| SCHEMBL23277161 | 0.78 | SMN1; SMN2 (0.50) | APPNPC1RAB9AMAOBIDO1 | |
| SCHEMBL30378200 | 0.77 | NPC1 (0.44) | NPC1RAB9AMAOBSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10758538-B2 | Heat shock protein binding compounds, compositions, and methods for making and using same | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2020-09-01 | — | — | US | disclosed |
| EP-3205647-B1 | 2-(PYRIMIDIN-5-YL)-THIOPYRIMIDINE DERIVATIVES AS HSP70 AND HSC70 MODULATORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2020-05-13 | — | — | EP | disclosed |
| US-20190038626-A1 | HEAT SHOCK PROTEIN BINDING COMPOUNDS, COMPOSITIONS, AND METHODS FOR MAKING AND USING SAME | MEMORIAL SLOAN-KETTERING CANCER CENTER | 2019-02-07 | — | — | US | disclosed |
| US-10052325-B2 | Heat shock protein binding compounds, compositions, and methods for making and using same | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2018-08-21 | — | — | US | disclosed |
| EP-3205647-A2 | 2-(PYRIMIDIN-5-YL)-THIOPYRIMIDINE DERIVATIVES AS HSP70 AND HSC70 MODULATORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | Memorial Sloan-Kettering Cancer Center (US) | 2017-08-16 | — | — | EP | disclosed |
| US-20170165265-A1 | HEAT SHOCK PROTEIN BINDING COMPOUNDS, COMPOSITIONS, AND METHODS FOR MAKING AND USING SAME | MEMORIAL SLOAN-KETTERING CANCER CENTER | 2017-06-15 | — | — | US | disclosed |
| US-9567318-B2 | Substituted pyrimidine compounds and uses thereof | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2017-02-14 | — | — | US | disclosed |
| WO-2011022440-A9 | HEAT SHOCK PROTEIN BINDING COMPOUNDS, COMPOSITIONS, AND METHODS FOR MAKING AND USING SAME | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2016-11-10 | — | — | WO | disclosed |
| EP-2467142-B1 | 2-(Pyrimidin-5-yl)-thiopyrimidine derivatives as Hsp70 and Hsc70 modulators for the treatment of proliferative disorders | SLOAN KETTERING INST CANCER (US) | 2016-09-21 | — | — | EP | disclosed |
| US-20120252818-A1 | HEAT SHOCK PROTEIN BINDING COMPOUNDS, COMPOSITIONS, AND METHODS FOR MAKING AND USING SAME | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2012-10-04 | — | — | US | disclosed |
| EP-2467142-A2 | HEAT SHOCK PROTEIN BINDING COMPOUNDS, COMPOSITIONS, AND METHODS FOR MAKING AND USING SAME | Memorial Sloan-Kettering Cancer Center (US) | 2012-06-27 | — | — | EP | disclosed |
| WO-2011022440-A2 | HEAT SHOCK PROTEIN BINDING COMPOUNDS, COMPOSITIONS, AND METHODS FOR MAKING AND USING SAME | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2011-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170165265-A1 | HEAT SHOCK PROTEIN BINDING COMPOUNDS, COMPOSITIONS, AND METHODS FOR MAKING AND USING SAME | HSPBP1, HSF1, HSPA2 | APP 955/4885NPC1 2801/4885RAB9A 4162/4885 |
| US-10758538-B2 | Heat shock protein binding compounds, compositions, and methods for making and using same | HSPBP1, HSF1, HSPA2 | APP 955/4885NPC1 2801/4885RAB9A 4162/4885 |
| US-20120252818-A1 | HEAT SHOCK PROTEIN BINDING COMPOUNDS, COMPOSITIONS, AND METHODS FOR MAKING AND USING SAME | HSPBP1, HSF1, HSPA2 | APP 955/4885NPC1 2801/4885RAB9A 4162/4885 |
| US-20190038626-A1 | HEAT SHOCK PROTEIN BINDING COMPOUNDS, COMPOSITIONS, AND METHODS FOR MAKING AND USING SAME | HSPBP1, HSF1, HSPA2 | APP 955/4885NPC1 2801/4885RAB9A 4162/4885 |
| US-10052325-B2 | Heat shock protein binding compounds, compositions, and methods for making and using same | HSPBP1, HSF1, HSPA2 | APP 955/4885NPC1 2801/4885RAB9A 4162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.